Follow Us On

Facebook  X  Linkedin  YouTube
 
 
 

Update on Medicare Operations: 

Telehealth, Claims Processing, and Medicare Administrative Contractors Status During the Shutdown


When certain legislative payment provisions (“extenders”) are scheduled to expire, CMS directs all Medicare Administrative Contractors (MACs) to implement a temporary claims hold. This standard practice is typically up to 10 business days and ensures that Medicare payments are accurate and consistent with statutory requirements. The hold prevents the need for reprocessing large volumes of claims should Congress act after the statutory expiration date and should have a minimal impact on providers due to the 14-day payment floor. Providers may continue to submit claims during this period, but payment will not be released until the hold is lifted.


Absent Congressional action, beginning October 1, 2025, many of the statutory limitations that were in place for Medicare telehealth services prior to the COVID-19 Public Health Emergency will take effect again for services that are not behavioral and mental health services. These include prohibition of many services provided to beneficiaries in their homes and outside of rural areas and hospice recertifications that require a face-to-face encounter. In some cases, these restrictions can impact requirements for meeting continued eligibility for other Medicare benefits. In the absence of Congressional action, practitioners who choose to perform telehealth services that are not payable by Medicare on or after October 1, 2025, may want to evaluate providing beneficiaries with an Advance Beneficiary Notice of Noncoverage. Practitioners should monitor Congressional action and may choose to hold claims associated with telehealth services that are not payable by Medicare in the absence of Congressional action. Additionally, Medicare would not be able to pay some kinds of practitioners for telehealth services.

Click here for more information.


CMS notes that the Bipartisan Budget Act of 2018 allows clinicians in applicable Medicare Shared Savings Program Accountable Care Organizations (ACOs) to provide and receive payment for covered telehealth services to certain Medicare beneficiaries without geographic restriction and in the beneficiary’s home. There is no special application or approval process for applicable ACOs or their ACO participants or ACO providers/suppliers. Clinicians in applicable ACOs can provide these covered telehealth services and bill Medicare for the telehealth services that are permissible under Medicare rules during CY 2025, irrespective of further Congressional action.

Click here for more information.


MACs will continue to perform all functions related to Medicare Fee-for-Service claims processing and payment.

Shutdown Halts Some Health Services as Political Risks Test Parties' Resolve

Stalemate centers largely on health coverage under the Affordable Care Act and Medicaid


Threats of a federal government shutdown have gone from being an October surprise to a recurring theme. This time around, though, the stakes are higher.


Federal funding ran out at midnight on Oct. 1, after Congress failed to pass even a stopgap budget while negotiations continued.


Now the question is how long the deadlock will last, with Democrats pitted against Republicans and a presidential administration that has broken with constitutional norms and regularly used political intimidation and primary threats to achieve its ends. Because Republicans hold only a slim majority in the Senate, any deal will need to attract at least a few Democratic votes.


Click here to read the full article.

CMS issued the proposed rule CMS-1832-P on July 16, 2025, titled Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program.

 

On September 11, 2025, ASIPP submitted a comment letter advocating for the following:

 

  1. Elimination of proposed efficiency adjustment, which is inappropriate, and efficiency is rather decreasing than increasing.
  2. Due to escalating costs, practice expense cuts applicable to independent physicians need to be addressed.
  3. Ambulatory Specialty Model (ASM) appears to be without any evidence and inappropriate, putting independent physicians at high risk for survival; consequently, this should be eliminated or conducted on a voluntary trial for five years.
  4. Telehealth services must be made permanent.

 

Here are ASIPP’s detailed comment letter, Chairman Comer’s recent letter to CMS and OMB, and 3 published articles addressing this issue:

 

Stay up-to-date with news that impacts you - visit our website or follow us on these social media platforms:

Facebook  LinkedIn  X  YouTube

October and November

ASIPP Webinars Announced!

The American Society of Interventional Pain Physicians (ASIPP) is pleased to invite Residents and Fellows to participate in our new Resident and Fellow Mentorship Program. This initiative has been developed to provide you with meaningful connections, guidance, and professional development opportunities as you advance in your training and prepare for your career in pain medicine. These meetings are designed to provide an open forum where you can seek advice on clinical challenges, career planning, research involvement, and strategies for professional success.

Join ASIPP on October 18, 2025, for an important webinar: Unveiling the Complexities of Controlled Substance Management in Interventional Pain Management (IPM).


Controlled substance management continues to present challenges for pain physicians, from evolving regulations and compliance requirements to balancing patient care with risk mitigation. This webinar will provide expert guidance to help you navigate these complexities and strengthen your practice.

Don’t miss the opportunity to engage with leading experts on October 21, 2025 as we explore how AI is transforming electronic health records and prescribing practices. This webinar is the first in a six-part series: the Modernizing Your Practice Through Medical Technology.

Each session focuses on a timely topic shaping the future of patient care—from electronic health records and AI prescribing to emerging tools that enhance efficiency, accuracy, and outcomes. Stay engaged each month and gain insights you can put into practice right away.

Join ASIPP on November 1, 2025, for our webinar Strategies for Successful Practice Management. This program will focus on practical approaches to strengthen your practice through improved documentation, compliance strategies, and effective practice-building techniques.


Whether you are looking to optimize workflows, ensure regulatory readiness, or position your practice for long-term growth, this webinar will provide valuable insights to support your success.

CDC Report Hints at the Effectiveness
of This Year's Flu Shot

In Southern Hemisphere, the vaccine offered 50% protection
against influenza-like illness

 

Key Takeaways


• In the Southern Hemisphere, the adjusted flu vaccine effectiveness rates against outpatient visits and hospitalizations were 50.4% and 49.7%.


• Only 21.3% of flu outpatients and 15.9% of hospitalized flu patients were vaccinated.


• Health authorities in the Northern Hemisphere might expect similar levels of protection against influenza, experts said.

Influenza vaccines have cut flu-associated outpatient visits and hospitalizations by half during the Southern Hemisphere's 2025 flu season, according to an interim analysis of surveillance data from eight countries.


Over the Southern Hemisphere's flu season from April through September, the adjusted vaccine effectiveness (VE) rate against outpatient visits associated with influenza-like illness (ILI) was 50.4% (95% CI 33.2-63.2), while the adjusted VE rate against hospitalizations for severe acute respiratory infection (SARI) was 49.7% (95% CI 46.3-52.8), reported Savanah Russ, PhD, of the CDC's National Center for Immunization and Respiratory Diseases, and colleagues.


Click here to read the full article.

Join Us in New Orleans for ASIPP 2026

Earn CMEs, Expand Networks, and Explore the Future of Pain Management

It is our pleasure to invite you to the American Society of Interventional Pain Physicians’ 2026 Annual Meeting, where we will continue to shape the future of Interventional Pain Management.


This 28th Annual Meeting will take place Thursday, March 19 through Saturday, March 21, 2026, at the Hilton New Orleans Riverside in New Orleans, Louisiana.


The 2026 Annual Meeting will provide the tools, knowledge, and connections you need to thrive in the evolving field of interventional pain management.

JOIN or RENEW your ASIPP Membership for the best registration rates.

Trump to Put 100% Import Taxes on Pharmaceutical Drugs

Tariffs would not apply to companies building manufacturing plants in the U.S.



President Donald Trump on Thursday said he will put import taxes of 100% on pharmaceutical drugs starting on Oct. 1.


The posts on his social media site showed that Trump's devotion to tariffs did not end with the trade frameworks and import taxes that were launched in August, a reflection of the president's confidence that taxes will help to reduce the government's budget deficit while increasing domestic manufacturing.


Under the Trade Expansion Act of 1962, the administration launched a Section 232 investigation in April about the impacts on national security from pharmaceutical drugs and other imports.


Click here to read the full article.

Our Sponsor

Our Sponsor





GLP-1s Don’t Increase Suicide Risk




It’s not uncommon for me, when discussing a GLP-1 medication with patients, to have them inquire about the drug’s purported risk in increasing suicidal ideation. What has never occurred? Patients asking about the possible benefits of GLP-1 medications to mood and to their decreasing the risk of suicidal ideation. 


On the face of existing data, that’s odd considering there is far more substantial evidence that GLP-1 users see improvements in mood: with no increase —and possibly decreased — risk of suicide. It’s not odd, though, when considering things through the lens of how risk is overestimated by the public along with the lens of weight bias where, at least with obesity medications, negative findings — however small, tenuous, or early — tend to be readily internalized and amplified, while positive findings are often minimized and ignored.


Where and how did the concern about suicide arise? On July 11, 2023, the European Medicines Agency (EMA) released a statement that, consequent to the Icelandic medicines agency’s highlighting three case reports involving suicide among GLP-1 users, they would be investigating further. 


Click here to read the full article.


Only three test dates left this year - Apply today!



October 25, November 15,

& December 13



  • ABIPP Part I

Four (4) hour virtual exam


  • ABIPP Path – Combined CCPM/ CSM Exam

For those with subspecialty in Pain Medicine

Two (2) hour virtual exam


  • ABIPP Competency Exam in IPM

For those without primary board certification

Two (2) hour virtual exam


  • ABIPP Competency Exam in Regenerative Medicine

Two (2) hour virtual exam


  • Controlled Substance Management Competency Exam

Two (2) hour virtual exam


  • Documentation, Coding, Compliance, Practice Management Competency Exam

Two (2) hour virtual exam

Exam Dates



Ob/Gyns Tell Patients Acetaminophen Is Safe in Pregnancy



Physicians and health organizations are reassuring patients that acetaminophen is safe to use during pregnancy after President Donald Trump said on Monday that the FDA will notify doctors that using the drug during gestation can be associated with a “very increased risk of autism.” 


Critics were quick to denounce the administration’s assertions, reassure patients, and point to decades of evidence contradicting Trump’s claims. 


Linking use of acetaminophen during pregnancy to autism is “irresponsible when considering the harmful and confusing message they send to pregnant patients, including those who may need to rely on this beneficial medicine during pregnancy,” said Steven J. Fleischman, MD, MBA, president of the American College of Obstetricians and Gynecologists (ACOG), in a statement.


Click here to read the full article.

Bipartisan and bicameral bills have been introduced to extend telehealth access through fiscal year 2027.


Telehealth services have become a crucial part of modern medical practice, especially since the COVID-19 pandemic. They provide numerous benefits to patients, helping to address issues like transportation barriers, missed work for caregivers, and financial strains. Medicare has played a key role in expanding access to telehealth, benefiting not only rural Americans but also the broader population, as most insurers—except United Healthcare Commercial— have adopted these policies.


The Telehealth Modernization Act of 2025, led by Reps. Buddy Carter (R-GA) and Debbie Dingell (D-MI), ensures continued access to telehealth services for seniors and patients nationwide. A companion bill is being advanced in the Senate by Sens. Tim Scott (R-SC) and Brian Schatz (D-HI).


Lawmakers emphasized the critical role of telehealth in reducing barriers to care, improving access for rural and underserved patients, and modernizing healthcare delivery.


This legislation represents a major step toward securing long-term telehealth access for Medicare patients and strengthening its place in the U.S. healthcare system.

Stay up-to-date with news that impacts you - visit our website or follow us on these social media platforms:

Facebook  LinkedIn  X  YouTube

Cannabis Product Beats Placebo
for Common Chronic Pain

Phase III trial shows efficacy, but lacks comparison
with other active treatments

Key Takeaways


• Cannabis extracts are believed to be helpful for nonsurgical back pain, but rigorous studies of their efficacy are limited.


• This placebo-controlled, randomized trial tested an investigational commercial cannabis product, VER-01, in patients with chronic low back pain.


• Patients assigned to VER-01 reported significantly greater pain relief over more than a year, but it's unclear how it might compare with other active therapies.

Patients with chronic low back pain experienced clinically significant relief when taking an investigational cannabis extract called VER-01 in a placebo-controlled trial, researchers said.


Pain ratings declined by nearly 3 points from a baseline average of 6.0 among patients who took VER-01 for 44 weeks, as well as among those initially randomized to placebo for 12 weeks who then switched to VER-01, according to Matthias Karst, MD, PhD, of Hannover Medical School in Germany, and colleagues.


Click here to read the full article.

 

We're excited to let you know that the new ASIPP Community, hosted by DocMatter, is now live!


The ASIPP Community on DocMatter will serve as a place for members to collaborate around clinical and research topics to advance the care of their interventional pain patients.


Click here to be a part of the conversation!




Blood Test for Alzheimer’s: Not a Predictor, Says Ethicist




The FDA recently cleared, for the first time, a blood test for Alzheimer's. This is very exciting news that has made many headlines. I think we have to exercise caution, care, and make sure patients and the families of patients with Alzheimer's, or worrying about Alzheimer's, really understand what this test is and is not.


This test is not a predictor of who's going to get Alzheimer's before symptoms have appeared. It is not intended to do that. If you think that your relative is exhibiting signs of Alzheimer's or has received a diagnosis of Alzheimer's, this blood test will confirm, through looking for amyloid plaques — the things that gunk up the brain in Alzheimer's — that they have gotten into the bloodstream. 


It can test for their presence and help confirm that what may be behavioral change, forgetfulness, or whatever the symptoms are, really is in fact Alzheimer's. It's exciting because I'm not sure current tests to confirm Alzheimer's are as accurate, but they're definitely more expensive. They often involve an MRI, trying to look at the brain and see if plaques are there. A blood test, I think, will be better as a way to confirm that Alzheimer's really is the correct diagnosis. 


Click here to read the full article.

Pain Medicine Case Reports (PMCR) and Editor-in-Chief Alaa Abd-Elsayed, MD, PhD would like to invite you to submit case reports and case series to the PMCR journal. Your article will be published free of charge.


Open access journals are freely available online for immediate worldwide open access to the full text of published articles. There is no subscription fee for open access journals. Open access journals are no different from traditional subscription-based journals: they undergo the same peer review and quality control as any other scholarly journal.


Interested in becoming a member of the PMCR Editorial Board?

Editorial board members are asked to review 2-6 manuscripts per year. Please submit your most up-to-date CV to sgold@asipp.org for consideration.


For more information or to submit your articles, click here.

We are excited to announce that Pain Medicine Case Reports (PMCR) journal (eISSN 2768-5152) has been accepted for inclusion in MEDLINE and PubMed, the prestigious bibliographic database of the U.S. National Library of Medicine. PMCR, a companion publication to the prestigious Pain Physician journal by ASIPP, joins its counterpart in achieving indexing in both MEDLINE and PubMed, marking ASIPP’s dual presence in these renowned databases.


The inclusion of PMCR journal in MEDLINE signifies a higher level of selectivity, as MEDLINE consists of the top 5,200 biomedical journals. This indexing also means that articles from PMCR will be searchable using NLM Medical Subject Headings (MeSH terms) and other metadata.


The selection for MEDLINE follows a rigorous evaluation process by reviewers from the Literature Selection Technical Review Committee (LSTRC). According to their criteria, the scientific quality of a journal’s content is the primary factor considered for indexing.


We extend our congratulations to the Pain Medicine Case Reports Editor-in-Chief, Deputy Editor-in-Chief, Journal Team, and Editorial Board for this achievement, which underscores the significance and excellence of this esteemed journal.

 

CASE REPORTS

Acute Rhabdomyolysis: A Rare Complication Subsequent to Intrathecal Dose Escalation: A Case Report


Jimmy Wen, BA, Sugamjot Badhan, BS, Ramy Khalil, BS, Shannon Dwyer, BA, Burhaan Syed, BS, and Foad Elahi, MD

 

Peripheral Neuromodulation for Treatment of Upper Extremity Complex Regional Pain Syndrome Following Peripherally Inserted Central Catheter Placement: A Case Report


Mohammed A. Alzarah, MB BCh BAO, Veena M. Do, MD, Mark S. Wallace, MD, Rodney A. Gabriel, MD, and Jeffrey L. Chen, MD

 

NEW ISSUE NOW AVAILABLE

 

HEALTH POLICY REVIEW

BMJ Publications on Interventional Techniques Do Not Meet Appropriateness Criteria of Conducting a Rapid Review: A Comprehensive Review


Laxmaiah Manchikanti, MD, Mahendra Sanapati, MD, Amol Soin, MD, Alan D. Kaye, MD, PhD, Alaa Abd-Elsayed, MD, Christopher G. Gharibo, MD, Allen Dennis, MD, and Joshua A. Hirsch, MD

 

HEALTH POLICY PERSPECTIVES

Escalating Growth of Spending on Medicare Advantage Plans: Save Medicare from Insolvency and Balance the Budget


Laxmaiah Manchikanti, MD, Mahendra Sanapati, MD, Paul J. Hubbell, III, MD, Ann Conn, MD, Mayank Gupta, MD, Ramarao Pasupuleti, MD, Alaa Abd-Elsayed, MD, and Alan D. Kaye, MD, PhD

 

Physician Payment Reform in Interventional Pain Management: Balancing Cost, Quality, Access, and Survival of Independent Practices


Laxmaiah Manchikanti, MD, Mahendra Sanapati, MD, Vidyasagar Pampati, MSc, Paul J. Hubbell, III, MD, Ann Conn, MD, Ramarao Pasupuleti, MD, Mayank Gupta, MD, Alan D. Kaye, MD, PhD, Alaa Abd-Elsayed, MD, Annu Navani, MD, Miles Day, MD, Devi Nampiaparampil, MD, Christopher G. Gharibo, MD, and Joshua A. Hirsch, MD

 

SYSTEMATIC REVIEW

Effectiveness of Peripheral Nerve Stimulation in Managing Chronic Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials


Laxmaiah Manchikanti, MD, Massab Bashir Khaira, MS, Amol Soin, MD, Alan D. Kaye, MD, PhD, Nebojsa Nick Knezevic, MD, PhD, Alaa Abd-Elsayed, MD, Mahendra Sanapati, MD, Vivekanand A. Manocha, MD, and Joshua A. Hirsch, MD




ASIPP is in collaboration with Curi Medical Liability Program




Since this malpractice insurance program officially launched in November 2018, ASIPP has signed up hundreds of providers with an average savings of 30%. This is professional liability insurance tailored to our specialty and will stand up for us and defend our practices. 

 

Curi is a full-service advisory firm that serves physicians and their practices. Their valued advice is grounded in your priorities and elevated in your outcomes. They are driven by a deep understanding of your specific circumstances in medicine, business, and life. To read a few important points to keep in mind about the program, including discounts, administrative defense, cyber coverage, aggressive claims handling, and complimentary risk management CME activities, visit our website.



IMPORTANT UPDATE

SPRINT no longer classified as PNT 



SPR is happy to announce an important update regarding Humana Medicare Advantage. As of May 1, Humana is now recognizing SPRINT as a PNS therapy. Previously, SPRINT was categorized as PNT (Percutaneous Nerve Stimulation), which allowed denials on the grounds that the therapy fell outside the NCD.


Additional details are as follows:

Payer: Humana Medicare Advantage (click here to view policy)

Policy Title: Peripheral Nerve Stimulators

Policy changes: SPRINT no longer misclassified as PNT and is now appropriately classified as PNS. Humana is applying the Noridian Medicare LCD criteria to ALL PNS devices – Including SPRINT PNS!

Effective Date: 5/1/2025


Click here to view a PDF of the official policy update.

 

Group Purchasing Organization Offer Better Pricing and Creates Added Value


ASIPP has formed a partnership with Henry Schein and PedsPal, a national GPO that has a successful history of negotiating better prices on medical supplies and creating value-added services for independent physicians. Working with MedAssets, PedsPal provides excellent pricing on products like contrast media that alleviate some of the financial pressures you experience today.



Learn More


For updated information concerning tariffs on products, click here.

 
 

ASIPP, Fedora Healthcare Solutions Partnership


ASIPP offers our members the benefit of a unique revenue cycle management/ billing service.



We have received a tremendous amount of interest in the ASIPP billing and coding program.




Click here to learn more about the negotiated rate for practices and more!

Like and Follow ASIPP® on Facebook, X, LinkedIn,

and YouTube for the most up-to-date news

related to you, your practice, and your patients!